Cargando…

Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma

SIMPLE SUMMARY: Hepatocellular carcinoma is the most common liver malignancy. In the population with an advanced stage of the disease, outcomes could be disappointed by treating with molecular targeting agents because of low treatment response rates. It has gained improving effects of immune checkpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hung, Hao-Chien, Lee, Jin-Chiao, Wang, Yu-Chao, Cheng, Chih-Hsien, Wu, Tsung-Han, Lee, Chen-Fang, Wu, Ting-Jung, Chou, Hong-Shiue, Chan, Kun-Ming, Lee, Wei-Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036568/ https://www.ncbi.nlm.nih.gov/pubmed/33807219 http://dx.doi.org/10.3390/cancers13071607

Ejemplares similares

Treatment strategy of adding transcatheter arterial chemoembolization to sorafenib for advanced stage hepatocellular carcinoma
por: Lee, Wei‐Chen, et al.
Publicado: (2020)

Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan
por: Chan, Kun-Ming, et al.
Publicado: (2019)

Risk Score Model for Microvascular Invasion in Hepatocellular Carcinoma: The Role of Tumor Burden and Alpha-Fetoprotein
por: Lee, Jin-Chiao, et al.
Publicado: (2021)

Living-Donor Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Score and Predictive Value of NLR on Survival
por: Hung, Hao-Chien, et al.
Publicado: (2022)

Recurrence Patterns After Hepatectomy With Very Narrow Resection Margins for Hepatocellular Carcinoma
por: Cheng, Chih-Hsien, et al.
Publicado: (2022)

Significance of Physical Status and Liver Function Reserve for Outcome of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib Treatment
por: Chan, Kun-Ming, et al.
Publicado: (2023)

Clinical relevance of alpha-fetoprotein in determining resection margin for hepatocellular carcinoma
por: Lee, Jin-Chiao, et al.
Publicado: (2019)

Preferred Treatment with Curative Intent for Left Lateral Segment Early Hepatocellular Carcinoma under the Era of Minimal Invasive Surgery
por: Wu, Tsung-Han, et al.
Publicado: (2022)

Individualized Selection Criteria Based on Tumor Burden in Future Remnant Liver for Staged Hepatectomy of Advanced CRLM: Conventional TSH or ALPPS
por: Chan, Kun-Ming, et al.
Publicado: (2022)

Modified preoperative score to predict disease-free survival for hepatocellular carcinoma patients with surgical resections
por: Lai, Yin, et al.
Publicado: (2022)

Improving outcomes of liver resection for hepatocellular carcinoma associated with portal vein tumor thrombosis over the evolving eras of treatment
por: Wang, Yu-Chao, et al.
Publicado: (2021)

Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection
por: Chan, Kun-Ming, et al.
Publicado: (2019)

Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma
por: Lee, Wei-Chen, et al.
Publicado: (2019)

Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma
por: Wu, Tsung-Han, et al.
Publicado: (2020)

Sedative and Immunosuppressive Effects of Dexmedetomidine in Transplantation
por: Lee, Chen-Fang, et al.
Publicado: (2021)

Significance of Hepatitis B Recurrence in Liver Transplantation Recipients
por: Chou, Hong-Shiue, et al.
Publicado: (2020)

Protein S for Portal Vein Thrombosis in Cirrhotic Patients Waiting for Liver Transplantation
por: Hung, Hao-Chien, et al.
Publicado: (2020)

A review of split liver transplantation with full right/left hemi-liver grafts for 2 adult recipients
por: Chan, Kun-Ming, et al.
Publicado: (2021)

Clinical Relevance of Isoagglutinin Rebound in Adult ABO-Incompatible Living Donor Liver Transplantation
por: Lee, Wei-Chen, et al.
Publicado: (2021)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Elevation of Lipid Metabolites in Deceased Liver Donors Reflects Graft Suffering
por: Lee, Wei-Chen, et al.
Publicado: (2023)

Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis
por: Tsai, Hong-Ming, et al.
Publicado: (2021)

Human Cytomegalovirus Is Associated with Lower HCC Recurrence in Liver Transplant Patients
por: Hsu, Po-Jung, et al.
Publicado: (2021)

Plasma cytomegalovirus DNA load predicts outcomes in liver transplant recipients
por: Hung, Hao‐Chien, et al.
Publicado: (2020)

Reconstruction of Separated Intrahepatic Ducts Using the Cystic and Common Hepatic Ducts in Right-Lobe Living-Donor Liver Transplantation: Experiences of Surgical Techniques, Biliary Complications, and Outcomes in a Single Institution
por: Hsu, Po-Jung, et al.
Publicado: (2022)

De Novo Endotoxin-Induced Production of Antibodies against the Bile Salt Export Pump Associated with Bacterial Infection following Major Hepatectomy
por: Chan, Kun-Ming, et al.
Publicado: (2018)

“Left at right” liver transplantation with heterotopic implantation of left liver graft in the right subphrenic space: Reappraisal and technical concerns for decision making
por: Chan, Kun-Ming, et al.
Publicado: (2019)

Salvage living donor liver transplantation for posthepatectomy recurrence: a higher incidence of recurrence but promising strategy for long-term survival
por: Chan, Kun-Ming, et al.
Publicado: (2019)

Impact of donor with evidence of bacterial infections on deceased donor liver transplantation: a retrospective observational cohort study in Taiwan
por: Chan, Kun-Ming, et al.
Publicado: (2019)

Adjustment of Immunosuppressants to Facilitate Anti-COVID-19 Antibody Production after mRNA Vaccination in Liver Transplant Recipients
por: Lee, Wei-Chen, et al.
Publicado: (2023)

Encouraging Split Liver Transplantation for Two Adult Recipients to Mitigate the High Incidence of Wait-List Mortality in the Setting of Extreme Shortage of Deceased Donors
por: Chan, Kun-Ming, et al.
Publicado: (2019)

Determinants of Antibody Response to SARS-CoV-2 Vaccines in Liver Transplant Recipients: The Role of Immunosuppression Reduction
por: Cheng, Chih-Hsien, et al.
Publicado: (2022)

The Preference for Anterior Approach Major Hepatectomy: Experience Over 3 Decades and a Propensity Score-Matching Analysis in Right Hepatectomy for Hepatocellular Carcinoma
por: Chan, Kun-Ming, et al.
Publicado: (2015)

Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis
por: Lee, Wei-Chen, et al.
Publicado: (2017)

Renal Function Improvement by Telbivudine in Liver Transplant Recipients with Chronic Kidney Disease
por: Lee, Wei-Chen, et al.
Publicado: (2017)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis
por: Chen, Ming-Yang, et al.
Publicado: (2016)

Hepatic arterial infusion chemotherapy and immune checkpoint inhibitors, alone or in combination, in advanced hepatocellular carcinoma with macrovascular invasion: a single-centre experience in Taiwan
por: Wu, Juei-Seng, et al.
Publicado: (2023)

Analysis of the recurrence risk factors for the patients with hepatocellular carcinoma meeting University of California San Francisco criteria after curative hepatectomy
por: Soong, Ruey-Shyang, et al.
Publicado: (2011)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gg4k294etk7lfgaoak6g5tc3j9